Download - Circulating Levels of Tumor Markers
-
8/12/2019 Circulating Levels of Tumor Markers
1/1
reast cancer is most common malignant disorder in
ibyan females. It is the most dreadful disease in terms
f quality of life, in spite of heart disease being more
ommon cause of mortality here. Benign and malignant
reast disorders are very common in Libyan women
milar to other Arab countries and particularly younger
ndividuals are affected here when compared with the
western population. This could be explained by the
ttribution of various factors such as the robust
pidemiological control of infectious diseases, increase
n the average life span of the general population,
igher socio-economic status, smoking, higher
ncidence of hepatitis B and C, food fads and socio-
conomic factors. Breast cancer is one of the leading
ancers, with an earlier age of onset in Libya and 26%
f all cancers belong to the category of breast cancers
n Libya as per the Benghazi cancer registry. Almost aecade ago, Singh and Al-Sudani demonstrated that
reast cancer is one of the top ten cancers responsible
or high mortality in Libya. In another study conducted
etween 1981 and 1985, breast cancer was the most
equent type (29.8%) in females and the majority of
hese patients were of a younger age group (72.3%
elow 50 years). Almost all the patients selected for our
tudy were multiparous and were breast-feeding. A
ecent literature review by Najjar and Easson provided
vidence that the average age of onset of breast cancer
n Arab women is 48 years, almost a decade sooner
han their western counterparts and this warrants
ffective screening and management strategies. The
resent study is a case control study of tumour markers
CA 125, CA 15-3 and Carcino-embryonic antigen (CEA)
n serum of patients suffering from benign and
malignant breast disorders in Libya.
Introduction
ata on sex hormone status in 11 cases of
onfirmed carcinoma of breast patients in the age
roup ranging from 30 55 years of age have
een retrieved from the department of surgery,
th October Hospital, Benghazi, Libya. This data
compared with 8 cases of benign fibroadenosis
nd 9 age matched controls free from both
malignant and benign disorders of breast in this
tudy. Venous samples from the patients and
ontrols were tested for serum CA125, CA15-
and CEA levels by authenticated methods by
sing Cobas E 411 analyser. Statistical analysis
as done by SPSS software using Mann-
Whitney and Wilcoxon tests.
The present study has shown high levels
of CA 15-3 and CEA only in malignant
disorders of breast. This result identifies
these biomarkers as the diagnostic and
prognostic markers for carcinoma
breast. CA 125 has not shown any
significance in this study proving that it
has no significance as a biomarker in
malignant breast disorders.
Table.1
Material and Methods
ResultsReferences
There is no significant rise of CA 125 in benign
(p=0814) and malignant (p= 0.676) disorders of
breast when compared to controls. CA 15-3 was
significantly high in patients suffering from breastcancer (p= 0.019) when compared to controls
and also very significantly high when (p= 0.003)
compared with patients with benign breast
disorders. However, the levels of CA 15-3 was
not significantly high in patients with benignbreast disorders (p=0.186) when compared to
controls. The level of CEA was significantly high
in patients of breast cancer when compared to
patients of benign breast (p=0.009) disorders and
(p=0.017) controls. However, the levels of CEA is
not significantly high in patients with benignbreast disorders (p=0.634) when compared to
controls. Results are summarized in table.1
Circulating tumor markers of benign and malignant breast disorders in Libya
J. R. Peela1, S. Shakila1, S. J. Dhoipode7 A. R. Said1, H. Beloch2S. Nang2 L. T. Peela3A. M. Jarari4S.O.Alsaeoti5H. El Awamy4N. M. Jarari6M. J. Kadeer4
1. Department of Biochemistry, Faculty of Medicine,Quest International University Perak, Ipoh, Malaysia
2. Faculty of Medicine,Quest International University Perak, Ipoh, Malaysia,
3. Great Eastern Medical School, Srikakulam, India,
4. Department of Biochemistry, Faculty ofMedicine,University of Benghazi, Benghazi, Libya.
5. Department of Surgery, Faculty of Medicine,University of Benghazi, Benghazi, Libya.
6. Department of Pharmacology, Faculty ofMedicine,University of Benghazi, Benghazi, Libya.
7.Department of Pharmacology, Guardian college of Dental Sciences and research centre,Ambernath,Thane,Maharastra,India .
Anim JT (1990) Breast cancer in Arab women: A
review. Emirates Med J 8: 189-195.
Elattar I (2005) Cancer in the Arab World:
Magnitude of the Problem. UICC March 21-25.El Mistiri M, Verdecchia A, Rashid I, El Sahli N, El
Mangush M, et al. (2007) Cancer incidence in
eastern Libya: the first report from the Benghazi
Cancer Registry, 2003. Int J Cancer 120: 392-
397.
Singh R, Al-Sudani OE (2001) Cancer mortality inBenghazi, Libyan Arab Jamahiriya, 1991-96.
East Mediterr Health J 7: 255-273.
Akhtar SS, Abu Bakr MA, Dawi SA, Huq IU
(1993) Cancer in Libya--a retrospective study(1981-1985). Afr J Med Med Sci 22: 17-24.Najjar H, Easson A (2010) Age at diagnosis of
breast cancer in Arab nations. Int J Surg 8:448-
452
Bielecka-Dbrowa A, Hannam S, Rysz J, Banach
M (2011) Malignancy- Associated Dyslipidemia.Open Cardiovasc Med J 5: 35-40.
Cheung KL, Graves CR, Robertson JF. Tumour
marker measurements in the diagnosis and
monitoring of breast cancer. Cancer Treat Rev
2000;26:91102.
Molina R, Filella X, Alicarte J, Zanon G, Pahisa J,Munoz M, et al. Prospective evaluation of CEA
and CA 15.3 in patients with locoregional breast
cancer. Anticancer Res 2003;23:10351041.
Gion M, Boracchi P, Dittadi R, Biganzoli E,
Peloso L, Mione R, et al. Prognostic role ofserum CA15.3 in 362 node-negative breast
cancers. An old player for a new game. Eur J
Cancer 2002;38:11811188.
Ebeling FG, Stieber P, Untch M, Nagel D,
Konecny GE, Schmitt UM, et al. Serum CEA
and CA 15-3 as prognostic factors in primarybreast cancer. Br J Cancer 2002;86:1217
1222.
Duffy MJ, Duggan C, Keane R, Hill AD,
McDermott E, Crown J, OHiggins N. High
preoperative CA 15-3 concentrations predict
adverse outcome in node-negative and node-positive breast cancer: study of 600 patients
with histologically confirmed breast cancer. Clin
Chem 2004;50:559563.
Molina R, Zanon G, Filella X, Moreno F, Jo J,
Daniels M, et al. Use of serial carcinoembryonicantigen and CA 15.3 assays in detecting
relapses in breast cancer patients. Breast
Cancer Res Treat 1995;36:4148.
Soletormos G, Nielsen D, Schioler V, Mouridsen
H, Dombernowsky P. Monitoring differentstages of breast cancer using tumour markers
CA 15-3, CEA and TPA. Eur J Cancer
2004;40:481486.
Molina R, Jo J, Filella X, Zanon G, Pahisa J,
Munoz M, et al. c-erbB-2 oncoprotein, CEA,
and CA 15.3 in patients with breast cancer:prognostic value. Breast Cancer Res Treat
1998;51:109119.
TypeCA125 CA15-3 CEA
Carcinoma
Breast
No of cases 11 11 11
Mean 90.97 92.90 12.53
Std Deviation 232.15 109.58 20.30Controls
No of cases 9 99
Mean 19.58 17.76 1.92
Std Deviation 16.88 6.34 .90
Fibroadenosis No of cases 8 8
8
Mean 17.92 13.38 1.57
Std. Deviation 15.77 4.36 .387
Conclusion